111 related articles for article (PubMed ID: 17368206)
1. FDG PET in preoperative assessment of colorectal liver metastases combining "evidence-based practice" and "technology assessment" methods to develop departmental imaging protocols: should FDG PET be routinely used in the preoperative assessment of patients with colorectal liver metastases?
Sheehan JJ; Ridge CA; Ward EV; Duffy GJ; Collins CD; Skehan SJ; Malone DE
Acad Radiol; 2007 Apr; 14(4):389-97. PubMed ID: 17368206
[TBL] [Abstract][Full Text] [Related]
2. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
3. Controversies in the management of colorectal liver metastases: role of PET and PET/CT.
Wiering B; Vogel WV; Ruers TJ; Oyen WJ
Dig Surg; 2008; 25(6):413-20. PubMed ID: 19212113
[TBL] [Abstract][Full Text] [Related]
4. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer.
Strasberg SM; Dehdashti F
J Surg Oncol; 2010 Dec; 102(8):955-9. PubMed ID: 21165998
[TBL] [Abstract][Full Text] [Related]
5. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
Wiering B; Ruers TJ; Oyen WJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
[TBL] [Abstract][Full Text] [Related]
6. A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables.
Tan MC; Castaldo ET; Gao F; Chari RS; Linehan DC; Wright JK; Hawkins WG; Siegel BA; Delbeke D; Pinson CW; Strasberg SM
J Am Coll Surg; 2008 May; 206(5):857-68; discussion 868-9. PubMed ID: 18471711
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET.
Rydzewski B; Dehdashti F; Gordon BA; Teefey SA; Strasberg SM; Siegel BA
AJR Am J Roentgenol; 2002 Feb; 178(2):353-8. PubMed ID: 11804891
[TBL] [Abstract][Full Text] [Related]
8. Impact of ¹⁸F-FDG-PET in decision making for liver metastectomy of colorectal cancer.
McLeish AR; Lee ST; Byrne AJ; Scott AM
ANZ J Surg; 2012; 82(1-2):30-5. PubMed ID: 22507492
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT.
Wildi SM; Gubler C; Hany T; Petrowsky H; Clavien PA; Jochum W; Gerlach T; Fried M; Mullhaupt B
J Clin Ultrasound; 2008 Jan; 36(1):20-6. PubMed ID: 17937421
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy.
Takahashi S; Kuroki Y; Nasu K; Nawano S; Konishi M; Nakagohri T; Gotohda N; Saito N; Kinoshita T
Anticancer Res; 2006; 26(6C):4705-11. PubMed ID: 17214330
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET for the pre-operative evaluation of colorectal liver metastases.
Arulampalam TH; Francis DL; Visvikis D; Taylor I; Ell PJ
Eur J Surg Oncol; 2004 Apr; 30(3):286-91. PubMed ID: 15028310
[TBL] [Abstract][Full Text] [Related]
12. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases.
Wiering B; Adang EM; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Ruers TJ; Krabbe PF; Oyen WJ
Nucl Med Commun; 2010 Nov; 31(11):938-44. PubMed ID: 20856152
[TBL] [Abstract][Full Text] [Related]
13. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet.
Zealley IA; Skehan SJ; Rawlinson J; Coates G; Nahmias C; Somers S
Radiographics; 2001 Oct; 21 Spec No():S55-69. PubMed ID: 11598248
[TBL] [Abstract][Full Text] [Related]
14. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease.
Denecke T; Steffen I; Hildebrandt B; Rühl R; Streitparth F; Lehmkuhl L; Langrehr J; Ricke J; Amthauer H; Hänninen EL
Acta Radiol; 2007 Oct; 48(8):821-30. PubMed ID: 17924212
[TBL] [Abstract][Full Text] [Related]
15. Role of FDG-PET in surgical management of patients with colorectal liver metastases.
Teague BD; Morrison CP; Court FG; Chin VT; Costello SP; Kirkwood ID; Maddern GJ
ANZ J Surg; 2004 Aug; 74(8):646-52. PubMed ID: 15315564
[TBL] [Abstract][Full Text] [Related]
16. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET.
Lin M; Shon IH; Wilson R; D'Amours SK; Schlaphoff G; Lin P
Hepatogastroenterology; 2007; 54(75):910-2. PubMed ID: 17591090
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases.
Truant S; Huglo D; Hebbar M; Ernst O; Steinling M; Pruvot FR
Br J Surg; 2005 Mar; 92(3):362-9. PubMed ID: 15672427
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of patients with liver metastases from colorectal cancer for locally ablative treatment with laser induced thermotherapy. Impact of PET with 18F-fluorodeoxyglucose on therapeutic decisions.
Amthauer H; Denecke T; Hildebrandt B; Rühl R; Miersch A; Nicolaou A; Ruf J; Plotkin M; Hänninen EL; Stroszczynski C; Gutberlet M; Langrehr J; Riess H; Ricke J
Nuklearmedizin; 2006; 45(4):177-84. PubMed ID: 16964344
[TBL] [Abstract][Full Text] [Related]
19. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases.
Pawlik TM; Assumpcao L; Vossen JA; Buijs M; Gleisner AL; Schulick RD; Choti MA
Ann Surg Oncol; 2009 Feb; 16(2):371-8. PubMed ID: 19020939
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
